# KBI Biopharma

> KBI Biopharma is a VC fund in Durham backing Biotechnology and Life Science. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Durham, United States
- Total investments: 3
- Last investment: Jan 2019
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kbi-biopharma
- X (Twitter): https://www.twitter.com/kbibiopharma
- Website: http://kbibiopharma.com
- Facebook: https://www.facebook.com/kbibiopharma

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally.With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug developmentprograms. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium.

## Contacts

5 contacts available for KBI Biopharma. Shizune tracks 8 team members at KBI Biopharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kbi-biopharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Life Science | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |
| Therapeutics | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Ireland | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Abhinav Shukla | Sr. Vice President, Process Development and Manufacturing | 0 | https://shizune.co/investors/profile/abhinav-shukla |
| Dirk T. Lange | CEO & President | 0 | https://shizune.co/investors/profile/dirk-t-lange |
| Doris Michor | Chief Operating Officer | 0 | https://shizune.co/investors/profile/doris-michor-939d |
| Jesse Kingg | VP Manufacturing & Site Head Commercial Mfg. Facility | 0 | https://shizune.co/investors/profile/jesse-kingg |
| Niket Bubna | Associate Director | 0 | https://shizune.co/investors/profile/niket-bubna |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Absci | Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $10.4M | Series D | Jan 07, 2019 |  |
| Comera Life Sciences | ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts. |  | Series A | Apr 04, 2018 |  |
| GlycoSeLect | GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in:- Basic R&D – Glycobiology & Glycoproteomics.- Biomarker Discover &Biomedical Diagnostics.- The Biopharmaceutical Industry.- Vaccines- CosmeticsGlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including:- Simplified, rapid & cost effective production through recombinant expression in Escherichia coli.- High purity & consistent performance.- Genetically enhanced glycan binding properties (specificity & affinity).- Scalable production facilitating utilization for large scale applications. | $494K | Seed | Oct 24, 2017 |  |

3 of 3 investments shown.

## Co-investors
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 1 deal together
- [JSR](https://shizune.co/investors/profile/jsr-corp) — VC Fund, 1 deal together
- [Phoenix Venture Partners](https://shizune.co/investors/profile/phoenix-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Biotech Investors in Ireland](https://shizune.co/investors/biotech-investors-ireland)
- [Biotech VC Funds in Ireland](https://shizune.co/investors/biotech-vc-funds-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Biotechnology VC Funds in Ireland](https://shizune.co/investors/biotechnology-vc-funds-ireland)

## FAQ

### What does KBI Biopharma invest in?

KBI Biopharma invests primarily in Biotechnology, Life Science and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact KBI Biopharma?

Public channels for KBI Biopharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at KBI Biopharma?

The team at KBI Biopharma includes Abhinav Shukla (Sr. Vice President, Process Development and Manufacturing), Dirk T. Lange (CEO & President) and Doris Michor (Chief Operating Officer), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co